Skip to NavigationSkip to content

Dr Lars Nieba appointed interim Chief Executive Officer at Nordic Nanovector

Published on: 09/03/20

Nordic Nanovector has appointed Dr Lars Nieba as the interim Chief Executive Officer. He is currently the company’s Chief Technology Officer and replaces Eduardo Bravo who as of today has left Nordic to pursue other career opportunities.

Neiba has a PhD from the Max-Planck-Institue for Biochemistery, Munchen and Institute for Biochemistry at the University of Zurich as well as an executive MBA from the University of St. Gallen in Switzerland. He worked at Cytos Biotechnology, then F. Hoffman-La Roche Ltd for 13 years in various leadership roles in operations, supply planning and biologics technology before joining Bayer AG in 2016. Here, he drove Bayer’s Chemistry, Manufacturing and Controls strategy for biologicals. He joined Nordic Nanvector on 1 December 2019.

Commenting on his appointment, Jan H. Egberts, Chairman of Nordic Nanovector, said: “The Board is very pleased to appoint Lars Nieba as Nordic Nanovector’s interim CEO. We believe that his significant operational, development and product supply expertise will be crucial as we work towards completing the PARADIGME study and prepare for the planned filing for Betalutin® with the FDA. On behalf of the Board I would like to thank Eduardo for his contribution as CEO.”

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches